GIOSTAR Chairman Dr. Anand Srivastava invited as Special Guest at the Prestigious Pravasi Bhartiya Divas Event in Indore.
Pravasi Bharatiya Divas (PBD) is celebrated once in every two years to strengthen the engagement of the overseas Indian community with the Government of India and reconnect them with their roots. During the Convention, selected overseas Indians are also honored with the prestigious Pravasi Bharatiya Samman Award to recognize their contributions to various fields both in India and abroad.
GIOSTAR has agreed to commercialize and promote DCGI (Indian FDA) approved stem cell therapies for Critical Lab Ischemia and Osteoarthritis to suffering masses in India and abroad that is developed by STEMPEUTICS Research Private Limited for Cipla and Kemwell Biopharma.
GIOSTAR, a pioneering global stem cell research organization, via STEMPEUTICS, an Indian biotechnology company which has developed DCGI – CDSCO (Indian FDA) approved stem cell product for Critical Limb Ischemia for Cipla and Osteoarthritis for Kemwell Biopharma entered into a commercial agreement with both Cipla and Kemwell Biopharma to commercialize and promote these two stem cell products/treatment to masses in India and abroad.
The partnership will leverage STEMPEUTICS’s expertise in developing innovative stem cell-based therapies and GIOSTAR’s global presence in the field of stem cell research and clinical expertise in stem cell treatments to address the unmet medical needs of patients suffering from critical limb ischemia and orthopedic conditions.
Headquartered in San Diego, California, U.S.A., the Global Institute of Stem Cell Therapy and Research (GIOSTAR) was founded in 2008 to provide affordable stem cell-based therapies to people across the planet suffering from genetic diseases and unable to afford the high cost of treatment.
The U.S. Department of Health and Human Services has recognized regenerative medicine as the next evolution of medical treatments. Also known as stem cell science, this field is not without any confusion about what is and is not possible in terms of cures within this emerging space. Interestingly, all major countries have heavily invested in stem cell science by funding their major universities. By the start of the millennium, gene therapy was already established, with proper research backing it. However, at that point of time, the primary challenge was to take it to the masses, as it was a highly complex field of science.
At this juncture 22 years ago, GIOSTAR’s chairman, Dr. Anand Srivastava, started exploring various possibilities in the modern filed of stem cell science. Affiliated with the University of California San Diego Medical College, University of California Irvine Medical College, Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), U.S.A. Dr. Srivastava was the pioneer in developing modern field of stem cell research at leading universities in the country. His early exploration in the stem cells field has led to the birth of GIOSTAR. The organization’s Co-founders, Dr. Anand Srivastava (Chairman) and Mr. Deven Patel (CEO & President), were driven by the focused vision to make this most advanced science affordable, available, and accessible to the masses around the world who are suffering from many incurable genetic and degenerative diseases and do not have access to this advance and expensive curative option.
Under the leadership of the Chairman Dr. Anand Srivastava and CEO, Mr. Deven Patel, GIOSTAR is working to develop stem cell transplant programs for four different state governments in India, with more than 155 million population. Before GIOSTAR, Mr. Patel served as the C.E.O., President, and Board of Directors in several highly comprehensive industries like healthcare, stem cell research, architecture, general construction, multifaceted internet industries, and alternative energy.
As an organization, GIOSTAR owes its profound success to both of its founders, working tirelessly for over two decades. Dr. Srivastava’s unique background and massive experience in stem cell biology, protein biochemistry, molecular biology, immunology, etc., coupled with Mr. Patel’s unwavering passion and total commitment to the organization’s vision, has proved to be pivotal in GIOSTAR’s success. This eventually led to the U.S.A. Congressional Recognition to both the founders for their efforts in spreading the advancement of stem cell science across the globe. They were also awarded the Asian Heritage Award for their business leadership in stem cell science. The Society of American Asian Scientists in Cancer Research(SAASCR) also honored Dr. Srivastava for his pionering contribution in the field of cancer research with their prestigious Outstanding Achievement Award for 2020.
Tackling the Pandemic
GIOSTAR is one of the first private companies in the world to get USA FDA approval in April 2020 to treat Covid-19 patients with its proprietary stem cell treatment under the US FDA Compassionate Use Program to treat acute inflammation of the lungs in hospitalized patients. Dr. Srivastava suggests, the initial data is promising for the use of stem cells as a viable option for critically ill Covid-19 patients and those suffering from several post-Covid complications. The organization is also preparing for a placebo-controlled, double-blind clinical trial to understand the measurable outcome of stem cell treatments in cases of post-Covid complications.
Social incidences like the great resignation, increased inflation, and quiet quitting are acting as economic disorders that further add to the already high cost of training medical professionals. Additionally, several other factors like shortage of skilled medical staff and investments required to develop new therapeutic agents getting out of control resulting in significantly high medical care costs.
GIOSTAR believes that the modern healthcare system focuses primarily on buying time to let the body heal itself; in other words, not many interventions are curative. Modern medicine treats specific diseases or organs as individual parts of the body, a very ineffective way to treat any medical condition. So, the entire healthcare system needs to change its approach, view the entire body as a unit, and develop therapies appropriately. This approach will pave a better way for finding effective cures for several diseases, primarily degenerative diseases.
Stem cells, being master cells of the body, are not only the unit of life but are also building blocks of the body. Because of this inherent nature, stem cells help repair damaged organs in a very systematic manner. In GIOSTAR’s scientific view, stem cells are the best treatment options for addressing several metabolic diseases and could be the least expensive treatment options.
Leading the Market and Innovation
GIOSTAR’s pioneering research has proved to the world the significance of stem cells for developing therapeutic approaches for several kinds of degenerative diseases. The peer-reviewed scientific research manuscripts on these therapies have been published in several respected medical journals.
GIOSTAR’s fundamental approach focuses on compassion to heal people from multiple incurable and devastating diseases. According to Dr. Srivastava, GIOSTAR does not see much competition as it provides cutting-edge research-based treatments, and others may take years to come close to what the GIOSTAR team has achieved. He says, “Our edge in the field is our pioneering and ground-breaking research work in the field of stem cell science, cancer research, and gene therapy for over 20 years”.
On the other hand, GIOSTAR CEO Mr. Patel shared a few of his thoughts on the commercial perspective of regenerative medicine development. He says, “The scientific research businesses are very competitive, both at a very high level of science and at the very high cost of doing it. Therefore, a simple advice to life science entrepreneurs is to narrow down your lucrative target research area and try to reach the finish line before you run out of money; otherwise, it is very easy to bankrupt the company in this highly inflated economy.”
As an organization, GIOSTAR plans to scale up its operations, keeping volatile markets in mind. Pertaining to its stable finances, the company’s pipeline of several technologies is very robust and in line with its projections. GIOSTAR is positioned to be the largest stem cell research and therapy provider.
The Future at GIOSTAR
At its core, GIOSTAR has been a research organization for over two decades. It has strategically and consistently invested in developing several of its scalable stem cell platforms, including,
Post Covid-19 Treatment Technology
Red Blood Cell Technology
Diabetes Treatment Technology
Stem Cell-based Skincare Technology
The organization is now making these stem cell technology companies public in the U.S.A., U.K., and E.U. stock markets. It is also planning to raise significant investments from institutional investors for clinical trials of its mature technologies. It has licensed its technology and created GIOWORLD Health Ltd. in the U.K., GIOWORLD Health Europe Ltd. in the European Union, and Celebration Life Sciences in the U.S.A. These companies will conduct several clinical trials in their respective jurisdiction using GIOSTAR’s proprietary stem cell technology platform.
GIOSTAR, A Cell Therapy and Research Institution is Leading Development of Therapies for Cancer, Metabolic and Degenerative Diseases
GIOSTAR is the world’s leading stem cell research institution located in San Diego, California, USA, and has been involved in stem cell research work for over 20 years. GIOSTAR’s team of scientists and clinicians has been involved in the development and utilization of clinical protocols related to stem cell transplants.
They have the capability to treat several devastating immunological diseases and blood-related diseases. These include Diabetes Type I and Type II, Lupus, Multiple Sclerosis, Crohn’s disease, Vasculitis, Scleroderma, Myasthenia Gravis, Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia and developing the therapies for Alzheimer’s disease, autism, anti-aging treatments, Parkinson’s disease, cancer, heart, and retinal degeneration, amyotrophic lateral sclerosis, neuropathy, osteoarthritis, paralysis, strokes, spinal cord injuries, skin burns and spinal muscular atrophy (SMA).
The company uses adult stem cells for its autologous and allogeneic stem cell therapy to treat patients. They have also generated blood stem cells from stem cells, which may have abilities to manage blood-related diseases such as betathalassemia and sickle cell anemia. Today, the company is a leading private organization with state-of-the-art excellence in the extraction of stem cells from the human body for therapeutic application.
Their patients normally suffer from metabolic diseases, cancer, and degenerative diseases. GIOSTAR has developed clinical protocols of stem cell therapies for treating autoimmune, degenerative, and metabolic diseases. They have also developed immune-therapy protocols for treating cancer.